• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复合自体乳化脂肪与浓缩生长因子治疗面部填充剂注射后脱发的临床疗效:一项单中心回顾性研究

Clinical Efficacy of Composite Autologous Chylated Fat and Concentrated Growth Factors for Treating Postinjection Alopecia After Facial Fillers: A Single-Center Retrospective Study.

作者信息

Tang Shuo, Zhou Guiwen, Fu Qiang, Chen Minliang

机构信息

Senior Department of Burns and Plastic Surgery, The Fourth Medical Center of Chinese PLA General Hospital, Beijing, , China.

Chinese PLA Medical School, Beijing, China.

出版信息

J Cosmet Dermatol. 2025 Jun;24(6):e70269. doi: 10.1111/jocd.70269.

DOI:10.1111/jocd.70269
PMID:40501302
Abstract

BACKGROUND

Postinjection alopecia is a rare but significant complication of facial fillers, likely caused by compromised microcirculation and follicular damage. Effective treatments are needed, but regenerative therapies specifically for this etiology lack systematic investigation.

OBJECTIVE

This study evaluated the efficacy and safety of combined autologous chylated fat (ACF) and concentrated growth factors (CGF) for treating acute alopecia following facial filler injection.

METHODS

In this single-center, retrospective case series, nine female patients with acute alopecia (2-4 weeks post-HA filler) were treated between June 2021 and June 2024. Treatment involved three monthly subcutaneous injections of a 1:1 ACF and liquid CGF mixture (0.1 mL/cm). Outcomes were assessed at 6 months posttreatment initiation, including hair density, diameter, terminal/vellus ratio, anagen/telogen ratio, Global Aesthetic Improvement Scale (GAIS), and adverse events.

RESULTS

All nine patients completed the 6-month follow-up. Significant improvements (p < 0.001) were observed at 6 months compared to baseline: hair density increased from 32.7 ± 13.4 to 92.4 ± 23.4 hairs/cm, hair diameter from 52.3 ± 15.2 to 75.8 ± 21.7 μm, terminal/vellus ratio from 0.31 ± 0.11 to 1.27 ± 0.35, and anagen proportion from 18.4% ± 6.5% to 63.7% ± 14.9%. GAIS scores indicated high satisfaction. Treatment was well-tolerated, with only one patient reporting transient erythema.

CONCLUSION

Combined ACF and CGF represent a promising and effective treatment for post-filler alopecia, offering a novel therapeutic option for early intervention and improved esthetic outcomes.

摘要

背景

注射后脱发是面部填充剂一种罕见但严重的并发症,可能由微循环受损和毛囊损伤引起。需要有效的治疗方法,但针对这种病因的再生疗法缺乏系统研究。

目的

本研究评估了自体乳化脂肪(ACF)和浓缩生长因子(CGF)联合治疗面部填充剂注射后急性脱发的疗效和安全性。

方法

在这个单中心回顾性病例系列中,2021年6月至2024年6月期间,对9名急性脱发女性患者(透明质酸填充剂注射后2至4周)进行了治疗。治疗包括每月皮下注射一次1:1的ACF和液体CGF混合物(0.1 mL/cm),共注射三次。在治疗开始后6个月评估结果,包括头发密度、直径、终毛/毳毛比例、生长期/休止期比例、全球美学改善量表(GAIS)和不良事件。

结果

所有9名患者均完成了6个月的随访。与基线相比,6个月时观察到显著改善(p < 0.001):头发密度从32.7±13.4根/cm增加到92.4±23.4根/cm,头发直径从52.3±15.2μm增加到75.8±21.7μm,终毛/毳毛比例从0.31±0.11增加到1.27±0.35,生长期比例从18.4%±6.5%增加到63.7%±14.9%。GAIS评分表明满意度较高。治疗耐受性良好,只有一名患者报告有短暂红斑。

结论

ACF和CGF联合治疗是填充剂后脱发的一种有前景且有效的治疗方法,为早期干预和改善美学效果提供了一种新的治疗选择。

相似文献

1
Clinical Efficacy of Composite Autologous Chylated Fat and Concentrated Growth Factors for Treating Postinjection Alopecia After Facial Fillers: A Single-Center Retrospective Study.复合自体乳化脂肪与浓缩生长因子治疗面部填充剂注射后脱发的临床疗效:一项单中心回顾性研究
J Cosmet Dermatol. 2025 Jun;24(6):e70269. doi: 10.1111/jocd.70269.
2
Dermal Filler-Induced Alopecia: A Case Report and Literature Review.真皮填充剂所致脱发:一例报告及文献综述
J Cosmet Dermatol. 2025 Feb;24(2):e16684. doi: 10.1111/jocd.16684. Epub 2024 Nov 20.
3
Fillers impacting follicles: the emerging complication of filler-induced alopecia.影响毛囊的填充物:填充物诱导脱发的新兴并发症。
Int J Dermatol. 2024 Sep;63(9):1131-1139. doi: 10.1111/ijd.17169. Epub 2024 Apr 14.
4
Cosmetic filler-induced hair loss: case series and literature review.美容填充剂所致脱发:病例系列及文献综述
J Dermatolog Treat. 2024 Dec 15;36(1):2443111. doi: 10.1080/09546634.2024.2443111. Epub 2025 Jan 28.
5
A Pilot One and Two-Year Prospective, Blinded Clinical Evaluation of Efficacy, and Safety of Combined Treatment With Crosslinked Hyaluronic Acid Dermal Filler and Barbed Polydioxanone Suspension Threads for Mid-Face Contour Enhancement.交联透明质酸真皮填充剂与倒刺聚二氧六环酮悬吊线联合治疗用于中面部轮廓改善的疗效和安全性的为期一年和两年的前瞻性、盲法临床试点评估。
J Cosmet Dermatol. 2025 Feb;24(2):e16700. doi: 10.1111/jocd.16700. Epub 2024 Dec 18.
6
Evaluation of the safety and efficacy of concentrated growth factors for hair growth promotion in androgenetic alopecia patients: A retrospective single-centre, single-arm study.评估浓缩生长因子对雄激素性脱发患者促进头发生长的安全性和有效性:一项回顾性单中心、单臂研究。
J Cosmet Dermatol. 2024 Dec;23(12):4051-4056. doi: 10.1111/jocd.16519. Epub 2024 Aug 21.
7
Hand Rejuvenation With A Hyaluronic Acid-Based Dermal Filler: A 12-Month Clinical Follow-Up Case Series.手部年轻化:基于透明质酸的真皮填充剂 12 个月的临床随访病例系列。
J Drugs Dermatol. 2021 Apr 1;20(4):451-459. doi: 10.36849/JDD.2021.5154.
8
Adverse Events Associated with Hyaluronic Acid Filler Injection for Non-surgical Facial Aesthetics: A Systematic Review of High Level of Evidence Studies.与非手术面部美容用透明质酸填充剂注射相关的不良事件:高证据水平研究的系统评价。
Aesthetic Plast Surg. 2024 Feb;48(4):719-741. doi: 10.1007/s00266-023-03465-1. Epub 2023 Aug 10.
9
High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study.一种能实现持久全脸容积恢复的透明质酸填充剂具有高患者满意度:一项为期18个月的开放性多中心研究。
Dermatol Surg. 2015 Dec;41(12):1361-9. doi: 10.1097/DSS.0000000000000549.
10
Effective and Safe Repeated Full-Face Treatments With AbobotulinumtoxinA, Hyaluronic Acid Filler, and Skin Boosting Hyaluronic Acid.使用阿柏西普肉毒素A、透明质酸填充剂和皮肤修复透明质酸进行有效且安全的全脸重复治疗。
J Drugs Dermatol. 2019 Jul 1;18(7):682-689.

本文引用的文献

1
Cosmetic filler-induced hair loss: case series and literature review.美容填充剂所致脱发:病例系列及文献综述
J Dermatolog Treat. 2024 Dec 15;36(1):2443111. doi: 10.1080/09546634.2024.2443111. Epub 2025 Jan 28.
2
Dermal Filler-Induced Alopecia: A Case Report and Literature Review.真皮填充剂所致脱发:一例报告及文献综述
J Cosmet Dermatol. 2025 Feb;24(2):e16684. doi: 10.1111/jocd.16684. Epub 2024 Nov 20.
3
CGF therapy: bridging androgenetic alopecia observations to psoriasis treatment via IL-17 pathway.CGF 疗法:通过 IL-17 通路将雄激素性脱发的观察结果与银屑病治疗联系起来。
Stem Cell Res Ther. 2024 Oct 8;15(1):353. doi: 10.1186/s13287-024-03959-y.
4
Evaluation of the safety and efficacy of concentrated growth factors for hair growth promotion in androgenetic alopecia patients: A retrospective single-centre, single-arm study.评估浓缩生长因子对雄激素性脱发患者促进头发生长的安全性和有效性:一项回顾性单中心、单臂研究。
J Cosmet Dermatol. 2024 Dec;23(12):4051-4056. doi: 10.1111/jocd.16519. Epub 2024 Aug 21.
5
Revitalizing Hair Growth: A New Regimen Utilizing Growth Factor Concentrate for Hair Loss Treatment.促进头发生长:一种利用生长因子浓缩物治疗脱发的新方案。
Cureus. 2024 Jun 28;16(6):e63354. doi: 10.7759/cureus.63354. eCollection 2024 Jun.
6
Evaluation of the effects of adding an adipose tissue-derived stromal vascular fraction to platelet-rich plasma injection in the treatment of androgenetic alopecia: A randomized clinical trial.评价富含血小板的血浆注射中添加脂肪组织源性基质血管成分治疗雄激素性脱发的效果:一项随机临床试验。
Skin Res Technol. 2024 Apr;30(4):e13700. doi: 10.1111/srt.13700.
7
Fillers impacting follicles: the emerging complication of filler-induced alopecia.影响毛囊的填充物:填充物诱导脱发的新兴并发症。
Int J Dermatol. 2024 Sep;63(9):1131-1139. doi: 10.1111/ijd.17169. Epub 2024 Apr 14.
8
Higher percentage of CD34+ stem cells and elevated efficacy in androgenetic alopecia treatment observed in CGF prepared from 640 nm laser-pretreated blood: A preliminary study.从 640nm 激光预处理后的血液中制备的 CGF 中,CD34+干细胞的比例更高,并且在治疗雄激素性脱发方面的效果更高:一项初步研究。
J Cosmet Dermatol. 2024 Jun;23(6):2249-2255. doi: 10.1111/jocd.16249. Epub 2024 Mar 1.
9
Bee Venom Stimulates Growth Factor Release from Adipose-Derived Stem Cells to Promote Hair Growth.蜂毒通过刺激脂肪来源干细胞释放生长因子促进头发生长。
Toxins (Basel). 2024 Feb 4;16(2):84. doi: 10.3390/toxins16020084.
10
Platelet-Rich Plasma (PRP) in Dermatology: Cellular and Molecular Mechanisms of Action.皮肤科中的富血小板血浆(PRP):作用的细胞和分子机制
Biomedicines. 2023 Dec 19;12(1):7. doi: 10.3390/biomedicines12010007.